- Home
- KZR vs HBIO Comparison
KZR vs HBIO Comparison
Compare KZR & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZR
- HBIO
- Stock Information
- Founded
- KZR 2015
- HBIO 1901
- Country
- KZR United States
- HBIO United States
- Employees
- KZR N/A
- HBIO N/A
- Industry
- KZR Biotechnology: Pharmaceutical Preparations
- HBIO Biotechnology: Laboratory Analytical Instruments
- Sector
- KZR Health Care
- HBIO Industrials
- Exchange
- KZR Nasdaq
- HBIO Nasdaq
- Market Cap
- KZR 29.7M
- HBIO 24.6M
- IPO Year
- KZR 2018
- HBIO 2000
- Fundamental
- Price
- KZR $4.01
- HBIO $0.53
- Analyst Decision
- KZR Hold
- HBIO Buy
- Analyst Count
- KZR 2
- HBIO 2
- Target Price
- KZR $9.00
- HBIO $3.00
- AVG Volume (30 Days)
- KZR 81.6K
- HBIO 1.0M
- Earning Date
- KZR 08-19-2025
- HBIO 08-11-2025
- Dividend Yield
- KZR N/A
- HBIO N/A
- EPS Growth
- KZR N/A
- HBIO N/A
- EPS
- KZR N/A
- HBIO N/A
- Revenue
- KZR N/A
- HBIO $91,397,000.00
- Revenue This Year
- KZR N/A
- HBIO N/A
- Revenue Next Year
- KZR N/A
- HBIO $9.75
- P/E Ratio
- KZR N/A
- HBIO N/A
- Revenue Growth
- KZR N/A
- HBIO N/A
- 52 Week Low
- KZR $3.62
- HBIO $0.28
- 52 Week High
- KZR $9.18
- HBIO $3.27
- Technical
- Relative Strength Index (RSI)
- KZR 38.90
- HBIO 57.82
- Support Level
- KZR $3.98
- HBIO $0.42
- Resistance Level
- KZR $4.23
- HBIO $0.64
- Average True Range (ATR)
- KZR 0.19
- HBIO 0.05
- MACD
- KZR -0.04
- HBIO 0.00
- Stochastic Oscillator
- KZR 9.56
- HBIO 49.00
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.